Quarterly report pursuant to Section 13 or 15(d)

Acquisition - Additional Information (Detail)

v3.19.3
Acquisition - Additional Information (Detail) - USD ($)
9 Months Ended
Jun. 11, 2018
Aug. 31, 2019
Aug. 31, 2018
Nov. 30, 2018
Business Acquisition [Line Items]        
Payment under asset purchase agreement     $ 10,500,000  
Common stock par value   $ 0.01   $ 0.01
Brand [Member]        
Business Acquisition [Line Items]        
Useful lives   1 year    
Customer Relationships [Member]        
Business Acquisition [Line Items]        
Useful lives   15 years    
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]        
Business Acquisition [Line Items]        
Aggregate consideration payable at closing under the Purchase Agreement $ 14,000,000      
Payment under asset purchase agreement $ 10,500,000      
Shares issued under asset purchase agreement 465,426      
Common stock par value $ 0.01      
Sale of stock price per share $ 7.52      
Percentage of earn out to be paid from gross revenues 75.00%      
Common stock deliver $ 200,000      
Common stock value 5,000,000      
Costs associated with the acquisition $ 580,000      
Discount rate 19.00%      
Long-term sustainable growth rate 3.00%      
Market royalty rate 1.00%      
Fair value of inventory $ 16,037,957      
Fair value of accounts receivable 188,019      
Fair value of prepaid expenses 68,867      
Short term deferred revenue 330,508      
Long term deferred revenue 1,074,898      
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Amount of earn out to be paid from sale of public cord blood inventory $ 500,000      
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Brand [Member]        
Business Acquisition [Line Items]        
Useful lives 1 year      
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Customer Relationships [Member]        
Business Acquisition [Line Items]        
Useful lives 30 years